Alternatives to NFL Biosciences

A global pharmaceutical and biotechnology corporation developing innovative medicines and vaccines for various therapeutic areas.

Biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing novel therapeutics to restore gut lymphatic function.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Enzyme-based technology to break down alcohol in the stomach.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Biopharmaceutical company developing and commercializing CNS disease treatments.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A biotechnology company developing genetic therapies for rare disorders.

Accelerating patient access to evidence-based innovation in mental health.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Pioneering vision restoration therapies for severe retinal degenerations.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing highly targeted, small molecule medicines.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing next-generation mRNA medicines.

A pharmaceutical company focused on developing long-acting injectable medicines.

AI-powered antibody discovery platform.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

AI platform for engineering molecular glues to create a new class of medicines.

Developing first-in-class oral therapy for BK polyomavirus infections.

Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.

A biotechnology company focused on oncology drug discovery.

Immunotherapy company targeting oncology and autoimmune diseases.

A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing novel male contraceptives.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.

Scalable, one-time curative in-vivo gene editing therapies.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Advancing targeted alpha therapies.